SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova - Quaterly Results

04 Feb 2022 Evaluate
The Sales for the quarter ended December 2021 of Rs. 186.70 million declined by -97.75% from Rs. 8289.40 millions.The Net Loss for the quarter ended December 2021 is Rs. -53.40 millions as compared to Net Profit of Rs. 646.50 millions of corresponding quarter ended December 2020The Operating Profit of the company witnessed a decrease to 32.30 millions from 1336.10 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 186.70 8289.40 -97.75 589.60 23436.40 -97.48 27095.00 31399.00 -13.71
Other Income 85.80 122.10 -29.73 1187.70 340.80 248.50 478.80 1732.30 -72.36
PBIDT 32.30 1336.10 -97.58 1135.80 4059.70 -72.02 4749.40 5441.40 -12.72
Interest 78.50 227.70 -65.52 225.30 897.00 -74.88 1018.00 1362.00 -25.26
PBDT -46.20 1108.40 -104.17 910.50 3162.70 -71.21 3731.40 4062.40 -8.15
Depreciation 16.00 298.50 -94.64 46.60 889.70 -94.76 999.70 1074.00 -6.92
PBT -62.20 809.90 -107.68 863.90 2273.00 -61.99 2731.70 2988.40 -8.59
TAX -8.80 163.40 -105.39 47.80 479.80 -90.04 586.90 -223.00 -363.18
Deferred Tax 9.70 0.00 0.00 -91.30 -4.80 1802.08 0.00 0.00 0.00
PAT -53.40 646.50 -108.26 816.10 1793.20 -54.49 2144.80 3211.40 -33.21
Equity 159.30 159.30 0.00 159.30 159.30 0.00 159.30 159.30 0.00
PBIDTM(%) 17.30 16.12 7.34 192.64 17.32 1012.09 17.53 17.33 1.15

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×